We therefore conducted the Neopearl study, a real-world research that aimed to assess the efficacy and safety of trastuzumab and NACT with or without pertuzumab in a large cohort of early-stage HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.